Small-dense versus large-buoyant LDL
LDL size blood testing captures the typical size and spread of the particles that ferry cholesterol in your blood (low-density lipoproteins, LDL). These particles originate in the liver as larger triglyceride carriers are trimmed down (very-low-density lipoproteins, VLDL), leaving LDL that can be bigger and more buoyant or smaller and denser. Each particle rides on a single scaffold protein (apolipoprotein B, apoB). The result summarizes whether your LDL pool is predominately larger versus smaller particles (large buoyant LDL; small dense LDL, sdLDL).
Size matters because it reflects how LDL is built and how it behaves in circulation. Smaller, denser particles tend to carry less cholesterol per particle, persist longer in the bloodstream, slip more readily into the artery wall, and are more prone to oxidative change; larger particles are typically cleared sooner. LDL size therefore mirrors the state of lipid remodeling influenced by triglycerides and liver enzymes that swap and trim fats (cholesteryl ester transfer protein, CETP; hepatic lipase). In short, it offers a window into LDL particle composition and traffic—how persistent, reactive, and artery-interacting your LDL is—beyond a simple cholesterol number.
Why particle character changes arterial behavior
LDL Size describes how big or small your LDL particles are—whether they are large and buoyant or small and dense. This matters because particle size influences how LDL behaves in blood vessels: smaller particles slip into artery walls more easily, oxidize faster, and linger longer, amplifying inflammation and plaque formation. It links liver lipid handling, insulin signaling, and vascular biology.
LDL Size measures the average diameter of LDL particles and the balance of small, dense versus large, buoyant LDL. Particle size matters because smaller LDL more easily enter artery walls, oxidize, and trigger inflammation, linking lipoprotein metabolism to cardiovascular risk, insulin signaling, liver fat handling, and vascular function.
Pattern A versus pattern B
Most labs classify results into a spectrum from small/dense to large/buoyant, sometimes labeled as pattern B versus pattern A. For risk, values toward the larger end are generally more favorable, but size is best interpreted alongside LDL particle number or ApoB and triglycerides.
When the measured size is low, it reflects a predominance of small, dense LDL. Physiologically, this points to insulin resistance and higher triglyceride exchange, yielding particles that are cholesterol-poor but artery-prone. People usually feel no symptoms, yet it often travels with abdominal weight gain, higher blood pressure, fatty liver, and low HDL. It's more common in men, increases after menopause, and appears in teens with obesity; in pregnancy, it can accompany insulin resistance states.
Low values usually reflect a shift toward small, dense LDL. This pattern arises when the liver overproduces triglyceride-rich VLDL (common with insulin resistance), followed by lipase and CETP remodeling that compresses LDL particles. System-level effects include greater arterial plaque formation, endothelial stress, and closer ties to metabolic syndrome, type 2 diabetes, and fatty liver. It is more frequent in men and increases after menopause; late pregnancy can also tilt toward smaller LDL as triglycerides rise.
Being in range suggests a balanced LDL distribution with fewer small, dense particles and steadier lipid transport. This aligns with lower atherogenicity, better endothelial function, and metabolic stability. For most assays, risk tends to be lower toward the higher end of the size reference.
When the size is high, particles are larger and typically align with lower triglycerides and better insulin sensitivity. This pattern can be reassuring, but not if the total number of LDL particles is elevated, as risk then tracks with ApoB despite size.
High values usually reflect larger, more buoyant LDL. This often accompanies lower triglycerides and better insulin sensitivity, with less remodeling toward dense particles. Larger LDL size does not negate risk from a high LDL particle number or markedly elevated LDL cholesterol, and some genetic lipid disorders can show larger LDL despite high risk. Premenopausal women typically have larger LDL than men of the same age.
What shifts particle remodeling and reported size
Interpretation varies by assay (NMR, gradient gel) and lab cutoffs. Fasting state, pregnancy, thyroid status, kidney disease, acute illness, and estrogen therapies or lipid-lowering drugs can shift particle remodeling and reported size.
A window into the metabolic quality of LDL
Big picture, LDL Size is a window into metabolic health. It integrates with ApoB/LDL-P, triglycerides, HDL, glucose, and inflammation to shape long-term atherosclerosis risk and cardiovascular outcomes.
FAQs
LDL Size testing assesses the average diameter and distribution of LDL particles—often reported as Pattern A (larger, buoyant) or Pattern B (small, dense)—using methods such as NMR, gradient gel electrophoresis, or ion mobility.
Testing LDL Size refines cardiovascular risk beyond LDL-C and ApoB by revealing particle atherogenicity. It can uncover small dense LDL, link results to metabolic health, and help track how lifestyle or therapy shifts your lipid pattern over time.
Test periodically to establish a baseline and monitor change. More frequent testing is useful during active lifestyle or treatment changes; less frequent testing is reasonable when results and habits are stable.
Dietary pattern (especially refined carbohydrates and saturated fat), triglyceride levels, insulin resistance, weight and visceral adiposity, physical activity, genetics, alcohol intake, smoking status, and certain medications can influence LDL Size.
Some laboratories request fasting to improve result comparability, especially when triglycerides are measured alongside LDL Size. Follow the specific instructions provided with your test.
Superpower currently offers at-home blood testing in the following states: Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin.
We’re actively expanding nationwide, with new states being added regularly. If your state isn’t listed yet, stay tuned.
References
- Feingold, K. R. (2024). Introduction to lipids and lipoproteins. In Endotext. MDText.com, Inc. https://www.ncbi.nlm.nih.gov/books/NBK305896/
- Hoogeveen, R. C., Gaubatz, J. W., Sun, W., Dodge, R. C., Crosby, J. R., Jiang, J., Couper, D., Virani, S. S., Kathiresan, S., Boerwinkle, E., & Ballantyne, C. M. (2014). Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. Arteriosclerosis, Thrombosis, and Vascular Biology, 34(5), 1069-1077. https://doi.org/10.1161/ATVBAHA.114.303284
- Garvey, W. T., Kwon, S., Zheng, D., Shaughnessy, S., Wallace, P., Hutto, A., Pugh, K., Jenkins, A. J., Klein, R. L., & Liao, Y. (2003). Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes, 52(2), 453-462. https://doi.org/10.2337/diabetes.52.2.453
- Feingold, K. R. (2026). Utility of advanced lipoprotein testing in clinical practice. In Endotext. MDText.com, Inc. https://www.ncbi.nlm.nih.gov/books/NBK355893/
- Sniderman, A. D., Williams, K., Contois, J. H., Monroe, H. M., McQueen, M. J., de Graaf, J., & Furberg, C. D. (2011). A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circulation: Cardiovascular Quality and Outcomes, 4(3), 337-345. https://doi.org/10.1161/CIRCOUTCOMES.110.959247






































.avif)
